What Pangea Bio does

Pangea Bio is a London-based clinical-stage biotechnology company (operating as Pangea Botanica Ltd, a UK private limited company) developing orally bioavailable, small-molecule therapeutics that selectively activate the Tropomyosin receptor kinase B (TrkB) receptor to promote neuronal survival and synaptic plasticity. Its lead candidate OT-003 received Clinical Trial Authorization from the UK MHRA in December 2025, initiating a Phase 1 clinical trial and formally transitioning the company to clinical-stage status. The pipeline also includes the OT-1xx next-generation TrkB activator series with diverse pharmacokinetic profiles suited to distinct neurological indications.

The company targets central nervous system and ophthalmic disorders with significant unmet need — including Parkinson's disease, Alzheimer's disease/dementia, schizophrenia (including treatment-resistant cases), major depressive disorder, and glaucoma — a market it highlights as encompassing tens to hundreds of millions of patients globally. Discovery is supported by its PangeaAI platform, which applies AI to identify drug-like molecules from nature's chemical space, augmented by historical human evidence of safety and efficacy. Pangea Bio also holds a 40% minority stake in spin-off Kanna Health (psychedelic-derived therapeutics) and is co-founded alongside Kadence Bio, a Phase 2-stage biotech developing an on-demand treatment for premature ejaculation.

Pangea Bio operates a pre-revenue, license-oriented business model with no commercial product; the company anticipates future revenue from pharmaceutical partnerships, licensing arrangements, and eventual product commercialization. Capital to date has been sourced entirely from non-dilutive grants — including One Mind Accelerator (USD 100,000, March 2024), Innovate UK Biomedical Catalyst (GBP 390,000, August 2024), and the Michael J. Fox Foundation (USD 1,000,000, October 2025) — supplemented by reported backing from the Alzheimer's Drug Discovery Foundation. The company is B Corp certified (impact score 85.5) and pursues a vertically segmented GTM strategy targeting enterprise pharmaceutical partners for clinical development and eventual commercialization of OT-003 and follow-on TrkB assets.

Name

Pangea Bio

Legal name

Pangea Botanica Ltd

Website

https://pangeabio.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Pangea Bio is a London-based clinical-stage biotech developing AI-supported, nature-inspired small molecules that selectively activate the TrkB receptor to treat central nervous system and ophthalmic disorders including Parkinson's, Alzheimer's, schizophrenia, depression, and glaucoma; lead candidate OT-003 is in Phase 1 trials.

Ownership category

akta.pro rank

Product category

CNS Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• CNS drug discovery
• Neurology therapeutics
• TrkB receptor modulators
• AI drug discovery
• Small molecule therapeutics

Headquarters

HQ city

Sevenoaks

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Development and Licensing: As a clinical-stage biotech, Pangea Bio generates revenue through pharmaceutical development, potential licensing deals, and eventual product commercialization. The company is developing OT-003 for CNS disorders and is seeking additional funding and partners for advancement.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Pangea Bio is a clinical-stage biotechnology company developing proprietary small-molecule selective activators of the TrkB receptor, led by asset OT-003 (Phase 1-ready after UK MHRA Clinical Trial Authorization) and the next-generation OT-1xx series, designed to promote neuroplasticity and treat central nervous system disorders including dementia, Parkinson's disease, schizophrenia, treatment-resistant depression, and glaucoma. Discovery is driven by the PangeaAI platform that applies AI to nature's chemical diversity combined with traditional human tolerability and efficacy evidence. The company pursues licensing and pharmaceutical partnerships for clinical development and commercialization.

Product overview

Pangea Bio is a clinical-stage biotech company developing a portfolio of CNS drug candidates centered on TrkB receptor activation. The core product pipeline consists of OT-003 (lead asset with CTA approval) and the OT-1xx series (next-generation TrkB activators), which work by promoting neuronal survival and synaptic plasticity. These are supported by the PangeaAI platform that leverages AI for nature-inspired drug discovery. The company also maintains strategic interests in spin-off companies including Kadence Bio (Phase 2 biotech) and Kanna Health (Pangea holds 40% stake), with both entities included in the B Corp certification.

Differentiator

Problem solved

Functional benefit

Products and services

• OT-003 Proprietary orally bioavailable small-molecule lead asset that selectively binds to and activates the Tropomyosin receptor kinase B (TrkB) receptor, generating downstream signaling that promotes neuronal survival, synaptic plasticity, reduces neuroinflammation, and decreases pathological protein aggregates (alpha-synuclein, amyloid-beta, tau). Indicated for central nervous system disorders including Parkinson's disease, dementia, schizophrenia, treatment-resistant depression and glaucoma; Phase 1-ready following UK MHRA CTA. Intended for out-licensing or co-development with pharmaceutical partners.
• OT-1xx Series TrkB Activators Preclinical pipeline of next-generation selective small-molecule TrkB activators with high oral bioavailability, brain penetration and solubility, designed to progress in distinct CNS disorders including Parkinson's disease. Licensed or co-development-ready for pharmaceutical partners seeking differentiated neuroplasticity candidates.
• PangeaAI Internal AI-powered drug discovery platform that deploys AI to identify promising molecules from nature's diverse chemical space, enhanced by traditional human evidence of tolerability and efficacy for accelerated development of CNS drug candidates. Used to drive Pangea Bio's TrkB activator pipeline discovery.

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature3 records

Partnerships

One partnership is on record.

• B Lab (B Corp Certification)coreOthers · 15 May 2024Pangea Bio completed B Corp certification through B Lab, the not-for-profit behind the B Corp movement, achieving an impact score of 85.5 points. This certification demonstrates high standards of social and environmental performance, transparency, and accountability.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Karuna Therapeutics: Acquired by Bristol Myers Squibb for $14B, developed xanomeline-trospium (Cobenfy) for schizophrenia, validating CNS mechanisms targeting muscarinic receptors. Comparable to Pangea because both pursue novel non-dopaminergic mechanisms for treatment-resistant schizophrenia and CNS disorders with high unmet need.
• Denali Therapeutics: Clinical-stage biotech developing therapeutics for neurodegenerative diseases including Parkinson's and Alzheimer's, with a focus on lysosomal function and neurodegeneration pathways. Comparable as a well-funded CNS biotech pursuing disease-modifying mechanisms for Parkinson's and related disorders.
• Sage Therapeutics: Commercial-stage CNS biopharma with approved neuroactive steroid Zurzuvae (postpartum depression) and a pipeline in major depressive disorder and epilepsy. Comparable because it pioneers novel CNS mechanisms (GABA receptor modulation) for treatment-resistant psychiatric disorders, similar to Pangea's neuroplasticity focus.
• Cerevel Therapeutics: Acquired by AbbVie for $8.7B, developed therapies for Parkinson's disease, schizophrenia, and epilepsy targeting dopamine and other CNS receptors. Comparable as a CNS-focused clinical-to-commercial stage biotech tackling similar neurodegenerative and psychiatric indications.

Direct peers

• Anavex Life Sciences: Clinical-stage biotech developing ANAVEX compounds targeting sigma-1 receptors for Alzheimer's, Parkinson's, and Rett syndrome. Comparable as a small-cap clinical-stage CNS biotech pursuing disease-modifying mechanisms across similar neurodegenerative indications.
• Neumora Therapeutics: Clinical-stage CNS biotech with a pipeline targeting neuroscience indications including schizophrenia and MDD. Comparable because it pursues precision neuroscience approaches for psychiatric and neurological diseases, mirroring Pangea's indication breadth and CNS focus.
• atai Life Sciences: Clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health indications including depression and PTSD. Comparable as a CNS-focused, neuroplasticity-oriented biotech co-founded by Lars Wilde via atai Beckley, with a similar platform-style pipeline approach.
• COMPASS Pathways: Clinical-stage CNS biotech developing psilocybin therapy for treatment-resistant depression. Directly comparable because CEO Lars Wilde and CBO Manon Veraart were co-founder and VP Business Development respectively, and both companies pursue neuroplasticity-driven mechanisms for CNS indications with high unmet need.
• Cassava Sciences: Clinical-stage biotech developing simufilam for Alzheimer's disease. Comparable as a clinical-stage neuroscience company targeting a major CNS indication with high unmet need and disease-modifying positioning.

Emerging players

• BioXcel Therapeutics: Clinical-stage biopharmaceutical company applying AI to neuroscience drug development, including agitation in Alzheimer's and schizophrenia. Comparable as an AI-enabled CNS biotech with multiple neuropsychiatric programs, similar in scale and stage to Pangea Bio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/pangea-bio

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pangea Bio